Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the additive efficacy of SIM versus placebo
in combination with leucovorin (folinic acid), irinotecan, and fluorouracil (FOLFIRI) as
measured by improvement in progression-free survival (PFS) in participants with metastatic
KRAS mutant colorectal adenocarcinoma who have progressed following a first-line oxaliplatin-
and fluoropyrimidine-containing regimen.